United Therapeutics board approves new $2 billion buyback

United Therapeutics Corporation (Nasdaq: UTHR) disclosed on October 22, 2026, that its board of directors has approved a new authorization to buy back up to $2 billion worth of its common shares. The company stated this new capital is available for use through October 21, 2027.

James Edgemond, the company's Chief Financial Officer and Treasurer, said the firm has the balance sheet and free cash flow to fund its long-term ambitions. He characterized the move as a reflection of the company's confidence in its future and its disciplined approach to allocating capital.

United Therapeutics explained that it may execute these purchases using accelerated share repurchase programs, open market trades, privately negotiated deals, or other methods. The firm noted that the program does not mandate buying any specific minimum number of shares. All repurchases remain at the company's discretion, contingent on alternative uses for capital and prevailing market conditions. United Therapeutics may start or stop these purchases at any time without giving prior notice and has stated it assumes no obligation to use the full authorization.

The company currently has an accelerated share repurchase transaction in progress that began in September 2026 under a previous authorization. This existing deal is scheduled to end in the fourth quarter of 2026, though its terms allow for earlier termination or extension. United Therapeutics specified that this ongoing transaction will not reduce the funds available under the new $2 billion authorization.

Founded by CEO Martine Rothblatt, United Therapeutics operates as a public benefit corporation focused on rare diseases and expanding the supply of transplantable organs. The press release included forward-looking statements regarding the company's expectations and plans, which are subject to risks described in its filings with the Securities and Exchange Commission. The company provided this information as of October 22, 2026, and stated it has no obligation to update or revise the details.